Home Blog Page 43

FMS 2026 | Longsys Chief Scientist Jian Chen Highlights the Storage Foundry Model for Edge AI

By
Advertorial Desk
-

SAN JOSE, Calif., Aug. 7, 2026 /PRNewswire/ — At FMS 2026 on August 5, Longsys (301308.SZ) Chief Scientist Dr. Jian Chen delivered a keynote speech titled “Intelligence at the Edge: Powered by the Storage Foundry Model,” addressing the new storage demands created as AI shifts from the cloud to the edge.

Intelligence at the Edge: Powered by the Storage Foundry Model
Intelligence at the Edge: Powered by the Storage Foundry Model

During the keynote, Dr. Chen introduced Longsys’ Storage Foundry Model and presented three edge AI storage innovations — HLCache™, iSA™ + AISSD™, and AIDIMM™ — designed to address key industry challenges including high DRAM costs, limited memory capacity, and bandwidth constraints, creating a new pathway for edge AI storage innovation.

Engineering Culture: The Foundation of Storage Innovation

Dr. Chen traced Longsys’ growth since its founding in 1999, including the launch of FORESEE, the acquisition of Lexar, expanded packaging and manufacturing through Longforce (Suzhou) Technology, and the integration of Brazil-based Zilia. Longsys now operates a global manufacturing network supporting worldwide delivery.

Rather than focusing solely on standardized products like traditional storage providers, Longsys applies full-stack engineering across eight areas — chip design, firmware development, material engineering, host software and OS-level adaptation, hardware design, packaging, automated testing, and mass production — enabling cross-domain hardware-software co-optimization and customized development. Together, these integrated capabilities across the storage value chain form the basis of the Storage Foundry Model.

Longsys Storage Foundry Model
Longsys Storage Foundry Model

Redefining Storage Collaboration for the Edge AI Era

Dr. Chen highlighted that while NAND Flash and DRAM have achieved significant cost reductions over decades, the rise of edge AI has introduced a new level of complexity. He described the fragmented edge AI landscape as a “thousand-handed challenge,” where diverse architectures, AI models, device forms, and applications require coordinated solutions rather than standardized approaches.

Thousand-handed challenge
Thousand-handed challenge

From AI PCs and mobile devices to industrial systems and robotics, different scenarios require tailored trade-offs among performance, power efficiency, form factor, and security. The Storage Foundry Model goes beyond conventional storage offerings by enabling solutions tailored to customers’ CPUs, SoCs, AI models, and system architectures — integrating hardware, firmware, and system-level optimization to accelerate development cycles and lower barriers to edge AI deployment.

Three Longsys Innovations Powering Edge AI

HLCache™ UFS leverages Longsys’ self-developed High-Level Cache technology to intelligently manage hot and cold data between UFS and DRAM, reducing memory pressure and improving multitasking performance on mobile AI devices.

iSA™ + AISSD™ enables efficient local AI inference for AI PCs and AI agent hosts by offloading MoE parameters and KV cache to dedicated SSD resources, reducing DRAM usage while supporting large-scale AI models.

AIDIMM™ addresses memory bandwidth challenges in AI BOX and edge AI systems with a plug-in high-bandwidth memory architecture, featuring a native 256-bit interface and up to 307.2GB/s bandwidth. Its flexible design simplifies system upgrades and reduces hardware redesign efforts.

AIDIMM
AIDIMM

“Collabovate”: Building the Future of Edge AI Together

Dr. Chen highlighted that as edge AI evolves from early adoption to large-scale deployment, diverse requirements across devices, architectures, and workloads cannot be addressed by a single product or technology.

To address this fragmented market, Dr. Chen introduced “Collabovate” — combining Collaboration and Innovation — as a new ecosystem collaboration approach. Through the Storage Foundry Model, Longsys is bringing together partners across chips, devices, and AI ecosystems to leverage complementary capabilities and accelerate customized edge AI solutions.

By opening its full-stack technology capabilities, Longsys aims to build a more collaborative storage ecosystem, enabling deeper industry collaboration and unlocking new possibilities for intelligent computing.

About Longsys

Founded in 1999, Longsys (301308.SZ) is a globally leading branded semiconductor memory enterprise, integrating R&D, design, packaging and testing, manufacturing, and sales services. For more information please visit https://www.longsys.com/, and follow Longsys on LinkedIn and Facebook.

NutriPQQ® Publishes New PQQ Sourcing Guide for Supplement Brands and Manufacturers

By
Advertorial Desk
-

The new B2B resource helps procurement, formulation, and quality teams evaluate PQQ production methods, ingredient identity, testing, stability, packaging, and supply continuity.

Key Highlights

  • Provides a practical framework for comparing PQQ suppliers beyond quoted price and assay percentage.
  • Covers production method, ingredient identity, analytical testing, batch consistency, formulation characteristics, packaging, storage, and supply continuity.
  • Supports procurement, quality, R&D, regulatory, and operations teams involved in ingredient qualification.

ALHAMBRA, Calif., Aug. 7, 2026 /PRNewswire/ — NutriPQQ®, a fermentation-produced pyrroloquinoline quinone disodium salt ingredient from Nutri Avenue Inc. with more than 99% purity, has published a new PQQ Sourcing Guide for dietary supplement brands, contract manufacturers, formulators, private-label developers, and ingredient purchasing teams.

Developed as part of NutriPQQ®’s B2B ingredient support resources, the guide helps buyers evaluate PQQ beyond headline price and assay percentage. It covers ingredient identity, production method, analytical testing, batch consistency, formulation characteristics, packaging, storage, documentation, and commercial supply continuity.

The new guide organizes these variables into a practical qualification framework. Buyers are encouraged to review PQQ identity, fermentation versus chemical synthesis, assay and analytical methods, impurities and contaminants, batch-to-batch consistency, formulation characteristics, storage conditions, packaging, shelf life, and commercial continuity before approving an ingredient or supplier.

For teams preparing requests for information or comparing multiple candidates, the framework is designed to bring procurement, quality, formulation, regulatory, and operations requirements into the same review process. This can reduce repeated information requests and make gaps easier to identify before sampling or commercial negotiation begins.

From Price Comparison to Supplier Qualification

The lowest initial quotation does not always represent the lowest total sourcing cost. Delays in documentation, inconsistent lots, unsuitable packaging, incomplete testing, formulation issues, or unexpected supply changes can create additional costs after purchase.

The guide therefore encourages procurement, quality assurance, R&D, regulatory, and operations teams to compare suppliers across quality, technical fit, documentation, commercial reliability, and service rather than price alone. Using a shared framework can also help teams identify unanswered questions and document supplier approval decisions before commercial purchasing begins.

NutriPQQ® is produced through fermentation and company materials specify more than 99% purity. Buyers evaluating PQQ can review additional NutriPQQ® product and science information covering production method, testing, and technical characteristics relevant to formulation and sourcing.

Availability

The complete PQQ Sourcing Guide is available on the NutriPQQ® website. Companies evaluating PQQ ingredients can also contact NutriPQQ® to request product specifications, technical documentation, samples, pricing, or formulation support.

The guide is intended as an educational starting point and does not replace a company’s internal quality system, regulatory review, or finished-product validation.

About NutriPQQ®

NutriPQQ® is a branded pyrroloquinoline quinone disodium salt ingredient from Nutri Avenue Inc. Produced through fermentation, it is positioned for dietary supplement brands, formulators, contract manufacturers, private-label developers, and ingredient sourcing teams. NutriPQQ® provides access to technical documentation, testing support, packaging options, and formulation guidance.

Media Contact

Nutri Avenue Inc.
Email: info@nutriavenue.com 
Phone: +1 423-393-7690
Address: 1101 W Valley Blvd, Ste 104, Alhambra, CA 91803
Website: www.nutripqq.com

Sunlight Real Estate Investment Trust (“Sunlight REIT”) Interim Results for the Six Months Ended 30 June 2026

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 7 August 2026 – Henderson Sunlight Asset Management Limited (the “Manager“) announces the interim results of Sunlight REIT for the six months ended 30 June 2026 (the “Reporting Period“).

For the Reporting Period, Sunlight REIT recorded revenue of HK$382.4 million, a year-on-year decline of 2.2%. After deducting property operating expenses of HK$82.7 million, net property income came in at HK$299.7 million. Aided by a 7.9% saving in cash interest expense to HK$84.3 million, distributable income for the Reporting Period was HK$164.0 million, a 2.7% drop from the corresponding period in the previous year.

The Board has resolved to declare an interim distribution per unit of HK 8.8 cents, representing a payout ratio of 94.3% and an annualized distribution yield of 8.1% based on the closing unit price of HK$2.16 on the last trading day of the Reporting Period.

The appraised value of Sunlight REIT’s portfolio was HK$17,118.1 million at 30 June 2026. Gross assets and net assets of Sunlight REIT were HK$17,728.3 million and HK$12,168.2 million respectively, and the net asset value per unit was HK$6.92.

Operating Highlights

At 30 June 2026, the overall occupancy rate of Sunlight REIT’s portfolio stood at 90.8%. Occupancy rates of the office and retail portfolios came in at 92.0% and 88.4% respectively, while their corresponding passing rents were HK$30.6 per sq. ft. and HK$62.2 per sq. ft., down 1.3% and 2.7% from six months ago.
Dah Sing Financial Centre, the flagship office property of Sunlight REIT, recorded an occupancy of 91.8%, while its passing rent stayed largely unchanged at HK$35.2 per sq. ft. Regarding the retail portfolio, the occupancy of Sheung Shui Centre Shopping Arcade came in at 86.9%, mainly attributable to the prolonged vacancy pending the replacement of a kindergarten tenant. Passing rent of this property was HK$98.2 per sq. ft. Meanwhile, Metro City Phase I Property reported an occupancy rate of 88.0%, while its passing rent was HK$52.0 per sq. ft.

Mr. Au Siu Kee, Alexander, Chairman of the Manager, said, “The sound financial position of Sunlight REIT provides a degree of assurance, as demonstrated by the favourable refinancing of over HK$3,600 million in debt facilities over the past 12 months. Meanwhile, we will prioritize strengthening operational resilience through disciplined cost management, prudent capital allocation and selective asset enhancement initiatives that support long-term value creation. In approaching its 20th listing anniversary, Sunlight REIT will endeavour to create sustainable value for the benefit of unitholders, while harnessing innovation and technology to bolster portfolio robustness and support future-ready asset management.”

Remarks: Attached financial highlights of 2026 interim results of Sunlight REIT.

Financial Highlights of 2026 Interim Results
(in HK$’ million, unless otherwise specified)

Six months ended

30 June 2026

Six months ended

30 June 2025

Change

(%)

Revenue 382.4 391.2 (2.2)
Net property income 299.7 307.4 (2.5)
Cost-to-income ratio (%) 21.6 21.4 N/A
Loss after taxation (124.1) (172.2) N/A
Distributable income 164.0 168.6 (2.7)
Distribution per unit (HK cents) 8.8 9.1 (3.3)
Payout ratio (%) 94.3 93.8 N/A
At 30 June

2026

At 31 December

2025

Change

(%)

Portfolio valuation 17,118.1 17,403.0 (1.6)
Net asset value 12,168.2 12,402.6 (1.9)
Net asset value per unit (HK$) 6.92 7.09 (2.4)
Gearing ratio (%) 28.3 27.8 N/A

Disclaimer: The information contained in this press release does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for units in Sunlight REIT in Hong Kong or any other jurisdiction.

Hashtag: #SunlightREIT #REIT

The issuer is solely responsible for the content of this announcement.

About Sunlight REIT

Listed on The Stock Exchange of Hong Kong Limited since 21 December 2006, Sunlight REIT (stock code: 435) is a real estate investment trust authorized by the Securities and Futures Commission, and constituted by the trust deed dated 26 May 2006 (as amended and restated) (the “Trust Deed”). It offers investors the opportunity to invest in a diversified portfolio of 11 office and six retail properties in Hong Kong with a total gross rentable area of approximately 1.3 million sq. ft. The office properties are located in both core and decentralized business areas, while the retail properties are situated in regional transportation hubs, new towns and urban areas with high population density.

About the Manager

The Manager of Sunlight REIT is an indirect wholly-owned subsidiary of Henderson Land Development Company Limited. Its main responsibility is to manage Sunlight REIT and all of its assets in accordance with the Trust Deed in the sole interest of its unitholders.

/C O R R E C T I O N — Trip.com Group/

By
Advertorial Desk
-

In the news release, Trip.com Group Releases 2025 Sustainability Report, Announces New Global Paid Paternity Leave Policy, issued 06-Aug-2026 by Trip.com Group over PR Newswire, we are advised by the company that it contains erroneous content . The complete, corrected release follows:

Trip.com Group Advances Sustainable Travel with Global Paid Paternity Leave Policy, SBTi-Validated Climate Targets, and USD 100 Million Tourism Innovation Fund

  • Eligible employees to receive a minimum of 20 days of paid paternity leave under new global policy
  • First online travel company in Asia Pacific with both near-term and net-zero emissions targets validated by SBTi
  • USD 100 million Tourism Innovation Fund launched to accelerate tourism innovation and destination growth

SINGAPORE, Aug. 7, 2026 /PRNewswire/ — Trip.com Group today reaffirmed its commitment to major sustainability initiatives spanning employee wellbeing, climate action and tourism innovation, alongside the release of its 2025 Sustainability Report. The Group also introduced a new global paid paternity leave policy of a minimum of 20 days for eligible employees. 


Structured around the Group’s “Friendly Four” framework – family-friendly, community-friendly, environmentally-friendly and stakeholder-friendly, the report highlights how Trip.com Group is translating its sustainability commitments into measurable action across its operations and the wider travel ecosystem. During the reporting period, the Group achieved Science Based Targets initiative (SBTi) validation for both its near-term and net-zero greenhouse gas emissions reduction targets, and launched a USD 100 million Tourism Innovation Fund, among other milestones.

“Travel connects people, cultures and communities, and we believe the future of travel must also create positive outcomes for the planet and society,” said Jane Sun, CEO of Trip.com Group. “Through our sustainability strategy, we are investing in our people, accelerating climate action and working with partners worldwide to build a more resilient tourism ecosystem.”

Supporting Families

Building on its existing efforts to foster a family-friendly workplace, Trip.com Group is introducing a global paternity leave policy that supplements local statutory entitlements and provides eligible employees with a minimum of 20 days of paid paternity leave. The first phase took effect on 1 August, covering selected markets across Asia, with additional regions joining in the second phase later this year. The expanded paternity leave enables eligible employees to devote more time to shared caregiving responsibilities and achieve greater balance between work and family life.

This latest initiative complements the Group’s existing childcare support programmes. Since its launch, its Childcare Subsidy has supported 2,038 families. In 2025, 1,114 employees benefited from the programme, with approximately USD 1.6 million invested. During the reporting period, the Group maintained a 100% return-to-work rate among female employees following maternity leave.

Trip.com Group also continued strengthening workplace diversity and inclusion. Women currently represent 33.1% of senior management positions and 52.3% of management roles in key revenue-generating functions. Women also account for 33.0% of STEM-related positions across the Group.

Empowering Communities

Trip.com Group continued to make travel more inclusive through initiatives that enhance the traveller experience and strengthen local tourism ecosystems by connecting communities, businesses and tourists.

Through its “Trip for Everyone” project, the Group enhanced accessibility across the travel planning and booking experience, including improvements to colour contrast, scalable typography, screen reader compatibility and keyboard navigation. This project received an iF Design Award for helping travellers with diverse physical and situational needs explore the world with greater autonomy.

The Group also expanded its Country Retreats programme, supporting local economic development through tourism. During the reporting year, the programme created more than 400 jobs and supported approximately 11,000 indirect employment opportunities. Cumulatively, the initiative has contributed to around 51,000 employment opportunities over the last five years, with local employees accounting for at least 80% of staff across 12 of its properties.

Providing timely assistance when travellers need it most remains central to the Group’s commitment to delivering a trusted and reliable travel experience. In 2025, Trip.com Group upgraded its Global SOS Platform to support 24 languages and 20 travel emergency scenarios. By the end of the year, the platform had handled more than 23,000 assistance requests across over 100 destinations. 

Protecting the Future of Travel

Across its operations and travel offerings, Trip.com Group continued advancing efforts to reduce its environmental footprint while helping travellers and corporate customers make lower-carbon choices throughout their journeys.

Trip.com Group became the first online travel company in Asia Pacific to have both its near-term and net-zero emissions reduction targets validated by the Science Based Targets initiative (SBTi), reinforcing its commitment to science-aligned climate action.

The Group also expanded its portfolio of more sustainable travel products across accommodation, flights, car rentals and rail. In 2025, 2.74 million users selected lower-carbon business travel options, resulting in 23.44 million lower-carbon travel bookings throughout the year.

Growing Tourism Together

Trip.com Group continued investing in innovation, destination development and partnerships that support the long-term growth of the tourism ecosystem.

At its 2025 Global Partner Conference, the Group launched its USD 100 million Tourism Innovation Fund to support innovative tourism projects and cross-sector collaborations that explore new approaches to destination development and create more distinctive visitor experiences.

As part of its efforts to support destination growth, Trip.com Group connects local businesses and tourism providers with travellers through a broad range of products and experiences. By the end of 2025, the Group offered more than 350,000 in-destination experiences worldwide, spanning dining and shopping, day tours, attraction and performance tickets, and customised tours. These offerings created new opportunities for local partners while enriching travellers’ journeys.

Looking ahead, Trip.com Group will continue advancing initiatives that make travel more inclusive, sustainable and beneficial for destinations and communities worldwide.

For more details on Trip.com Group’s progress, key priorities and continued commitment to building a more inclusive, sustainable and resilient future for travel, please download the full 2025 Sustainability Report here.

About Trip.com Group

Trip.com Group is a global travel service provider comprising Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group is on the mission “to pursue the perfect trip for a better world”. Find out more about Trip.com Group here: group.trip.com.

Follow us on: X, Facebook, LinkedIn, and YouTube.

HCLTech named among the world’s most sustainable companies by TIME magazine

By
Advertorial Desk
-

NEW YORK and NOIDA, India, Aug. 7, 2026 /PRNewswire/ — HCLTech (NSE: HCLTECH) (BSE: HCLTECH), a leading global technology company, has been named to TIME’s World’s Most Sustainable Companies 2026 list, marking its second consecutive year to receive the recognition. This year, HCLTech ranks among the top five global professional services companies and is the highest-ranked India-headquartered company in the category.

Compiled by TIME in collaboration with Statista, the ranking assesses more than 5,800 global companies across more than 20 sustainability indicators spanning commitments and ratings, reporting and transparency, and environmental and social stewardship.

The recognition reflects HCLTech’s continued focus on aligning with the UN Global Compact and Sustainable Development Goals. In FY26, the company set a new benchmark in water leadership by replenishing 51 times more water than it consumed and retained zero waste-to-landfill platinum certification across all owned facilities. HCLTech has accelerated its net-zero journey by achieving its 2030 SBTi-validated emissions target four years ahead of schedule.

“Being recognized by TIME for a second consecutive year reflects the progress we are making in embedding sustainability deeper into the core of our business and advancing our net-zero ambition for 2040,” said Vipul Arora, Global Head of Sustainability at HCLTech. “Our focus remains on scaling impact through innovation, partnerships and responsible practices that enable long-term value for our clients, communities and the broader ecosystem.”

To learn more about HCLTech’s sustainability journey, visit: www.hcltech.com/sustainability/2026-sustainability-report

About HCLTech

HCLTech is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around AI, digital, engineering, cloud and software, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology & Services, Semiconductor, Telecom and Media, Retail and CPG, Mobility and Public Services. Consolidated revenues as of 12 months ending June 2026 totaled $14.8 billion. To learn how we can supercharge progress for you, visit hcltech.com.

For further details, please contact:

Meredith Bucaro, Americas – meredith-bucaro@hcltech.com
Elka Ghudial, Europe – elka.ghudial@hcltech.com
James Galvin, APAC – james.galvin@hcltech.com
Nitin Shukla, India, Middle East & Africa – nitin-shukla@hcltech.com

Alebund’s AP301 NDA Accepted for Review by China’s NMPA

By
Advertorial Desk
-

SHANGHAI, Aug. 7, 2026 /PRNewswire/ — Alebund Pharmaceuticals (Jiangsu) Limited (“Alebund” or the “Company”; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving maintenance dialysis, is formally accepted for review by China’s National Medical Products Administration (NMPA) today. The NDA is supported primarily by the results of RESPOND-1, the pivotal Phase III clinical trial of AP301 completed in China, together with other accumulated clinical data.

AP301 is a novel fiber-iron-based phosphate binder that offers high phosphate-binding capability, does not require chewing before swallowing, does not expand in volume when exposed to gastric fluid, and is not systemically absorbed. These features contribute to a reduced pill burden, improved tolerability, and enhanced patient adherence.

AP301 China Pivotal Phase III Trial (RESPOND-1)

RESPOND-1 was a randomized, open-label, active-controlled, multicenter pivotal Phase III clinical trial conducted at 50 sites in China and led by Professor Li Zuo, Director of the Department of Nephrology at Peking University People’s Hospital. A total of 474 patients with hyperphosphatemia receiving maintenance dialysis were randomized in a 3:1 ratio to AP301 (355 patients) or sevelamer carbonate (119 patients) for a 52-week treatment period, with doses in both groups titrated to the same serum phosphate target.[4]

The trial met both of its pre-specified primary efficacy endpoints. The AP301 maintenance dose demonstrated clinically and statistically significant superiority over the ineffective low dose in reducing serum phosphate levels, and the efficacy of AP301 was robust and sustained throughout the entire 52-week treatment period, meeting the endpoint of non-inferiority to sevelamer carbonate in reducing serum phosphate levels as designed in the trial. AP301 was safe and well tolerated. The most common adverse events were discolored feces and diarrhea. Diarrhea generally occurred early in treatment and resolved without any change to treatment.

At Week 12, the AP301 group was non-inferior to the active comparator sevelamer carbonate group in reducing serum phosphate levels least-squares mean reductions from baseline of 0.72 mmol/L ([2.22 mg/dL] vs. 0.70 mmol/L [2.22 mg/dL] vs. 0.70 mmol/L [2.17 mg/dL], respectively); the upper bound of the 95% confidence interval (CI) for the between-group difference (0.06 mmol/L [0.20 mg/dL]) was below the pre-defined non-inferiority margin of 0.19 mmol/L (0.59 mg/dL), demonstrating that AP301 met the pre-specified non-inferiority criterion.

During the low-dose control period (from the end of Week 24 to the end of Week 27), among AP301 responders (serum phosphate <1.78 mmol/L [5.5 mg/dL] at the end of Week 20) who were re-randomized 1:1, serum phosphate control in the AP301 maintenance-dose group (94 patients) was superior to that in the AP301 ineffective low-dose control group (93 patients), with a between-group difference of -0.58 mmol/L (-1.8 mg/dL) (P<0.001), which was both clinically and statistically meaningful. 

At Week 52, the AP301 group showed a greater mean reduction in serum phosphate level from baseline than the sevelamer carbonate group (0.76 mmol/L [2.35 mg/dL] vs. 0.72 mmol/L [2.22 mg/dL]), a higher serum phosphate target attainment rate (66.7% vs. 58.6%), and a lower mean daily dose exposure (AP301 6.52 g/day vs. sevelamer carbonate 7.56 g/day). AP301 achieved a robust and sustained reduction in serum phosphate levels throughout the 52-week treatment period[4].

AP301 was generally safe and well tolerated over the 52-week treatment period. The most common adverse events were discolored feces and diarrhea. Diarrhea generally occurred early in treatment and resolved without any change to treatment. In addition, no notable iron-overload risk signal was observed during the 52-week treatment period.

Results from RESPOND-1 were presented at the American Society of Nephrology (ASN) Kidney Week 2025.[4]

Further details of the trial are available at clinicaltrials.gov under identifier NCT07030595, or at www.chinadrugtrials.org.cn under registration number CTR20231624.

Hyperphosphatemia and Unmet Medical Need

Hyperphosphatemia is a common complication in patients with CKD receiving dialysis, affecting approximately 95% of patients with end-stage renal disease (“ESRD”) on dialysis.[1] Chronically elevated serum phosphate is associated with vascular calcification, secondary hyperparathyroidism and renal osteodystrophy, as well as increased risks of cardiovascular events and all-cause mortality.[2] Regular dialysis and dietary phosphorus restriction are generally insufficient to adequately control the phosphate burden, and patients often require long-term pharmacological treatment. Despite the widespread use of phosphate binders, according to data from China Insights Consultancy, approximately 76% of dialysis patients in China fail to achieve the target serum phosphate range of 1.13–1.78 mmol/L [3.5–5.5 mg/dL];[1] separately, according to 2021 data from the Dialysis Outcomes and Practice Patterns Study (DOPPS), approximately 52% and 39% of hemodialysis patients in the United States and Japan, respectively, had serum phosphate levels above 1.78 mmol/L [5.5 mg/dL].[3] Existing therapies continue to face challenges in gastrointestinal tolerability, pill burden and long-term treatment adherence, and innovative treatment options that combine efficacy, tolerability and dosing convenience remain to be further developed.[1-3]

Dr. Gavin Guoyao Xia, Co-founder, Chairman of the Board, and Chief Executive Officer of Alebund Pharmaceuticals, said: “The NMPA’s acceptance of the NDA for AP301 marks a key step in advancing Alebund’s proprietary products from clinical development toward commercialization, and an important milestone in our global strategy. Hyperphosphatemia requires long-term management, yet reconciling efficacy, safety and adherence remains a core challenge in clinical care today. As a potential best-in-class oral phosphate binder, AP301 can genuinely offer patients with chronic kidney disease on dialysis a long-term treatment option that brings together efficacy, tolerability and dosing convenience. Building on this acceptance, we will actively support the review process and, drawing on our manufacturing base in Yangzhou, accelerate our preparations for launch. We look forward to bringing this innovation from China to patients with kidney diseases around the world.”

Jin Tian, M.D., Co-founder and Chief Medical Officer of Alebund Pharmaceuticals, commented: “Achieving the sustained serum phosphate control within the target range over the long term remains a major challenge for patients with chronic kidney disease on dialysis. Results from the AP301 China Phase III pivotal study confirmed that this novel iron-based phosphate binder effectively lowers phosphorus, is safe, and well tolerated. We will work closely throughout the review process and continue to advance the global clinical development of AP301, with the goal of making a new phosphate lowering product available to patients as soon as possible.”

References

[1] CIC, Global and Chinese Hyperphosphatemia Drug Industry Blue Book, 2023.

[2] KDIGO 2017 Clinical Practice Guideline Update. Kidney Int Suppl. 2017;7(1):1–59.

[3] Guedes M, et al. Kidney Med. 2023;5(2):100584. doi:10.1016/j.xkme.2022.100584.

[4] Zuo L, et al. J Am Soc Nephrol. 2025;36(10S):TH-PO1200. doi:10.1681/ASN.202556bnmcy8.

About Alebund Pharmaceuticals

Alebund Pharmaceuticals (09637.HK) is a biopharmaceutical company focused on kidney disease and related chronic conditions, aiming to bring better therapies to patients worldwide. It has one of the broadest renal-focused pipelines and an integrated platform spanning R&D, manufacturing and commercialization. Its portfolio comprises seven investigational drug candidates and one commercialized product, Mircera®. Three of the candidates are at the clinical stage: AP301 (Phase III; China Pivotal Phase III trial completed, global MRCT ongoing), AP306 (Phase II) and AP303 (Phase I). Together they address chronic kidney disease (CKD) and its complications, including hyperphosphatemia, renal anemia, IgA nephropathy, diabetic kidney disease, FSGS and ADPKD. Alebund has built a manufacturing site in Yangzhou, Jiangsu to support the future commercial manufacturing of AP301 and other pipeline products and has obtained a Drug Manufacturing License (Category B) issued by the Jiangsu Provincial Drug Administration. The Company has also established a dedicated nephrology sales team responsible for the commercialization of relevant products in China. For more information, visit www.alebund.com. 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding clinical development plans, expected timing of data, product potential and future development. These statements are based on the Company’s judgments and assumptions as of the date of this press release and are subject to various risks and uncertainties; actual results may differ materially from such forward-looking statements. This press release does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

ASTRI Achieves Strongest Representation in Asia at 2026 R&D 100 Awards, with Three Technologies Named Global Winners

By
Advertorial Desk
-

HONG KONG, Aug. 7, 2026 /PRNewswire/ — The Hong Kong Applied Science and Technology Research Institute (ASTRI) has achieved a landmark milestone at the prestigious 2026 R&D 100 Awards, widely regarded as the “Oscars of Innovation”. ASTRI secured six finalist technologies, making it the highest-represented organisation in Asia and the leading non-US organisation among the 2026 R&D finalists. Of these six finalist technologies, three were selected as R&D 100 Award winners, earning places among the world’s 100 most technologically significant innovations of the year.


Ir Dr Ted Suen, Chief Executive Officer of ASTRI, said: “We are deeply honoured to be recognised by the R&D 100 Awards. Having six technologies shortlisted as finalists and seeing three of them selected as winners is a strong testament to ASTRI’s research excellence and innovation capabilities. These achievements reflect the dedication of our researchers and partners in developing technologies that address real-world industry and societal challenges while creating economic and social values.”

“ASTRI will continue to strengthen collaboration among government, industry, academia and the research ecosystem, accelerate the commercialisation of research outcomes, and contribute to Hong Kong’s development as an international innovation and technology hub. We also support the national 15th Five-Year Plan by advancing strategic technologies in areas such as AI, microelectronics, new energy and green technologies, helping to foster new quality productive forces and contribute to the country’s high-quality development,” he added.

Six Technologies Recognised by the 2026 R&D 100 Awards

ASTRI’s six recognised technologies span advanced surveillance, sustainability, healthcare, advanced materials and next-generation manufacturing.

R&D100 Award Winners

Category

Technology

Mechanical/Materials

DyeMate-SC

Waterless dyeing is becoming increasingly important amid water scarcity and tightening regulations on microplastics. While supercritical CO₂ dyeing works for synthetic fibres, natural fibres remain incompatible with the process. DyeMate-SC overcomes this barrier, enabling supercritical CO₂ dyeing of natural fibres with performance comparable to conventional water dyeing while reducing resource consumption and environmental impact.

Mechanical/Materials

EcoFlux: EcoCarbon-infused Natural Graphite Anode

Co-applicant: Graphex Innovation and Technology Limited

EcoFlux Anode redefines spherical natural graphite through hard carbon infilling and a fast-ion coating developed using an eco-friendly aqueous process. This innovation delivers less than 5% anode swelling, charging capability in under 20 minutes, enhanced reversible capacity and nearly double the cycle life, offering a cost-effective, high-performance solution for long-life and high-energy battery applications.

Process/Prototyping:

CarbonTrust

Co-applicant: Yau Lee Group

CarbonTrust addresses key challenges through purpose-built technical solutions that combine blockchain immutability, AI Anomaly Detection and Cross-registry Intelligence in a unified platform. The platform integrates three mutually reinforcing innovations into a single subscription-accessible service, making trusted, automated carbon verification commercially viable for the first time at urban scale.

R&D100 Award Finalists

Category

Technology

Electrical – Safety and Security

Multispectral Imaging for Advanced Surveillance Operations

The Omniguard multispectral imaging system delivers superior haze penetration, exceptional contrast and outstanding signal clarity. By harnessing short-wave infrared (SWIR) technology operating at wavelengths of 900-1700nm, the system cuts through atmospheric scattering far more effectively than visible-light cameras, enabling reliable long-range detection even in foggy or smoky conditions.

Mechanical/Materials

Biocide-Free Bacteria-Repellent Nanofiber Breathing System Filters

Co-applicant: Well Lead Medical Co., Ltd.

The bacteria-repellent nanofiber filter provides enhanced protection by controlling bioburden in breathing circuits. Its non-biocidal zwitterionic polymer hydration layer repels over 95% of bacteria without chemical leaching or superbug development. Robust physical filtration achieves over 99.999% bacterial and viral filtration and over 98.5% particle efficiency, consistently outperforming conventional electrostatic filters, whose effectiveness decline over time.

Process/Prototyping

100% Closed-loop Post-consumer Recycled Plastic Sheets for Cargo Industry

Co-applicant: Hong Kong Air Cargo Terminals Limited (Hactl)

The 100% closed-loop recycled plastic sheets are made from post-consumer polyethylene cargo sheet waste. Through an innovative recycling process, advanced formulation and a three-layer film structure, the recycled materials achieve the high melt strength required for large-sheet film blowing without the use of virgin resin, while meeting cargo operational requirements and promoting waste reduction and circular sustainability.

Organised by internationally renowned publication R&D World, the R&D 100 Awards honour the world’s 100 most-technologically significant innovations from around the globe each year. Entries are evaluated by an independent panel of industry experts, making the awards among the most respected and competitive recognitions in global research and development. ASTRI’s success highlights both the institute’s research excellence and Hong Kong’s growing influence in the international innovation landscape.

About ASTRI

Founded in 2000 by the HKSAR Government, Hong Kong Applied Science and Technology Research Institute (ASTRI) is the city’s largest government-funded R&D centre. Committed to transforming high-impact research into practical innovations, ASTRI drives market-driven, interdisciplinary advancements across sectors, including Smart City, FinTech, Digital Health and Life Sciences, New Industrialisation and Intelligent Manufacturing, Application-Specific Integrated Circuits (ASIC) and Advanced Electronics, New Energy and Energy Storage, and Green and ESG Technologies. Following its merger with the Nano and Advanced Materials Institute, ASTRI has further strengthened its capabilities, with over 1,500 patents and 2,200 successful cases of technology transfer. Recognised with numerous international awards, ASTRI continues to nurture top I&T talent and foster collaborations among the I&T ecosystem, contributing to Hong Kong’s high-value economic development. For more information, please visit: https://www.astri.org

Swing Amid Black‑Rock Greenery! Discover Another Way to Holiday in Hainan

By
Advertorial Desk
-

HAIKOU, China, Aug. 7, 2026 /PRNewswire/ — A news report from PDDC:

Looking for a different kind of getaway in Hainan, away from the usual coastal sightseeing? Mission Hills Haikou is an outstanding choice. Nestled within volcanic terrain, the resort features golf courses, soothing natural hot springs and a diverse range of attractions. It is a hidden gem integrating sports, wellness and leisure, perfect for family trips, gatherings with friends or laid‑back short vacations.

Step onto the iconic Blackstone Course and immerse yourself in the charm of mountain‑style golf. This professional championship‑grade venue covers 350 acres, stretches over 7,888 yards with a par of 73, and is dotted with 147 distinctive sand traps, delivering professional specifications and ample challenges. Fairways are wrapped in lush greenery amid dense woods. Primitive volcanic rocks scatter across the landscape, where green hills, forests and exotic rock formations create picture‑perfect natural scenery ideal for photos. With wide‑open spaces and fresh woodland air far from urban hustle, every swing feels relaxed and effortless. Built on the age‑old volcanic lava platform of Haikou Yangshan, the course is dotted with ancient lychee trees. Dark basalt rocks interweave with tropical vegetation, preserving Hainan’s one‑of‑a‑kind volcanic mountain landscape. Playing golf here feels like wandering through a natural volcanic ecological park.

Blackstone Course, Mission Hills Haikou Resort, Haikou City, Hainan Province, P.R.China
Blackstone Course, Mission Hills Haikou Resort, Haikou City, Hainan Province, P.R.China

Unlike conventional golf venues, Mission Hills Haikou is built on distinctive volcanic rock landforms, delivering a truly unique experience. Its ten courses vary in style and difficulty, showcasing natural grasslands, exposed volcanic bedrock and Australian‑style sand belts. Undulating sand surfaces and natural rock hazards add fun and challenge to every shot. Visitors can enjoy the elegance and thrill of golf while soaking in Hainan’s one‑of‑a‑kind volcanic landscape for both visual delight and rewarding gameplay.

Golf is only part of the diverse, all‑in‑one relaxing holiday experience at Mission Hills. After an energetic round, head to the hotel sky lounge for panoramic views over rolling green hills and the golf courses, and savour peaceful slow moments. Or visit the Volcanic Hot Spring Valley, sink into a warm hot‑spring pool. Home to a Guinness‑certified large‑scale cluster of volcanic mineral‑spring pools rich in natural mineral elements, the valley offers special volcanic grotto hot‑spring pools as well as herbal baths ihonfused with tropical blossoms, allowing guests to fully embrace the wellness gifts brought by volcanic geothermal energy.

Boasting comprehensive, well‑developed facilities, the resort offers high‑quality vacation experiences. It brings together golf, volcanic hot springs, Movie Town, duty‑free outlets and lively food night markets, offering everything you need for dining, entertainment, shopping and wellness in one place. Step into Feng Xiaogang Movie Town, where Nanyang‑style arcade‑house streets recreate the old‑time local vibe of Hainan for an immersive taste of Southeast Asian charm.

Drawing on its outstanding cultural‑tourism resources, Mission Hills Haikou continues to refine its offerings and enhance visitor experiences. It develops diverse, custom‑tailored travel routes adapted to different seasons. Whether you are a golf enthusiast or a traveller seeking slow‑paced wellness retreats, you can find your own perfect holiday joy here.

1...424344...6,440Page 43 of 6,440